HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use EUCRISA safely and effectively. See full prescribing information for EUCRISA.
EUCRISA® (crisaborole) ointment, for topical use
Initial U.S. Approval: 2016
RECENT MAJOR CHANGES
INDICATIONS AND USAGE
EUCRISA is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. (1)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Ointment, 2%. (3)
Known hypersensitivity to crisaborole or any component of the formulation. (4)
WARNINGS AND PRECAUTIONS
Hypersensitivity reactions: If signs and symptoms of hypersensitivity occur, discontinue EUCRISA immediately and initiate appropriate therapy. (5.1)
The most common adverse reaction occurring in ≥1% in subjects is application site pain. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.